Rhabdoid tumor predisposition syndrome 2: genes and variants
Explore variant evidence for Rhabdoid tumor predisposition syndrome 2 across 2 analyzed proteins (SMARCA4, SMARCB1). Linked ClinVar records include 10 pathogenic or likely pathogenic variants, 1,563 variants of uncertain significance and 144 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Rhabdoid tumor predisposition syndrome 2
SMARCA4: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4
Its ATPase activity drives nucleosome remodeling in BAF-family complexes and thereby controls access to regulatory DNA. Germline pathogenic variants cause Coffin-Siris syndrome or rhabdoid-tumor predisposition, while somatic loss defines several aggressive cancers.
10 ClinVar pathogenic / likely pathogenic and 1,681 uncertain variants in SMARCA4 have source records linked to Rhabdoid tumor predisposition syndrome 2. Association strength is not clinical gene validity.
SMARCB1: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1
Within SWI/SNF complexes, it constrains oncogenic transcription and supports normal chromatin regulation. Biallelic tumor-cell inactivation is characteristic of malignant rhabdoid tumors, while germline variants predispose to rhabdoid tumors or schwannomatosis.
0 ClinVar pathogenic / likely pathogenic and 26 uncertain variants in SMARCB1 have source records linked to Rhabdoid tumor predisposition syndrome 2. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Rhabdoid tumor predisposition syndrome 2
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| SMARCA4 R1203C | 1203 | Helicase C-terminal | Pathogenic / likely pathogenic (★★) |
| SMARCA4 Y732H | 732 | Pathogenic / likely pathogenic (★) | |
| SMARCA4 Y732F | 732 | Pathogenic / likely pathogenic (★) | |
| SMARCA4 R1157W | 1157 | Helicase C-terminal | Pathogenic / likely pathogenic (★) |
| SMARCA4 G719D | 719 | RNA-binding region which is sufficient for bindi | Pathogenic / likely pathogenic (★) |
| SMARCA4 K755E | 755 | Pathogenic / likely pathogenic (★) | |
| SMARCA4 L768P | 768 | Helicase ATP-binding | Pathogenic / likely pathogenic (★) |
| SMARCA4 G784W | 784 | Helicase ATP-binding | Pathogenic / likely pathogenic (★) |
| SMARCA4 G951A | 951 | Pathogenic / likely pathogenic (★) | |
| SMARCA4 T1032N | 1032 | Pathogenic / likely pathogenic (★) |
Which prediction tools work for Rhabdoid tumor predisposition syndrome 2
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- CATVariant: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 89 out of 100
- PolyPhen-2: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 87 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 87 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 84 out of 100
- ESM1b (LLR): 83 out of 100
- MutPred: 82 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Diseases related to Rhabdoid tumor predisposition syndrome 2
- Coffin-Siris syndrome, also linked to SMARCA4 and SMARCB1
- Non-small cell lung carcinoma, also linked to SMARCA4
- Lung adenocarcinoma, also linked to SMARCA4
- NK-cell enteropathy, also linked to SMARCB1
- Medulloblastoma, also linked to SMARCA4
- Head and neck squamous cell carcinoma, also linked to SMARCA4
Frequently asked questions
Which genes have records linked to Rhabdoid tumor predisposition syndrome 2?
This view contains 2 analyzed proteins: SMARCA4, SMARCB1. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 10 pathogenic or likely pathogenic variants, 1,563 variants of uncertain significance and 144 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 1,776 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center